What is Mesosil?
Mesosil specializes in the development of next-generation anti-infective solutions, leveraging a unique silica-based platform that facilitates the high-capacity delivery and sustained release of bioactive agents. By integrating seamlessly into existing manufacturing workflows, the company provides a critical value proposition for dental material producers looking to mitigate recurrent tooth decay. Beyond dentistry, Mesosil is actively exploring high-growth applications in orthopedics and implantable medical devices, aiming to enhance the longevity and safety of biomaterials through long-term antimicrobial protection. Their technology represents a significant shift in how medical devices manage infection risks, moving away from traditional surface coatings toward integrated, material-level solutions.
How much funding has Mesosil raised?
Mesosil has raised a total of $1.6M across 1 funding round:
Angel/Seed
$1.6M
Angel/Seed (2024): $1.6M with participation from NorthSpring Capital Partners, ArchAngel Network of Funds, Centre for Aging and Brain Health Innovation, GreenSky Capital, and GreyHill Group
Key Investors in Mesosil
NorthSpring Capital Partners
NorthSpring Capital Partners invests in passionate entrepreneurs and companies developing unique intellectual property, providing financial resources and expertise to accelerate growth in the technology corridor.
ArchAngel Network of Funds
Archangel is a Canadian investment network focused on early-stage companies, emphasizing innovation and excellence by connecting resilient founders with a collaborative ecosystem of angel-stage investors.
Centre for Aging and Brain Health Innovation
CABHI is a solution accelerator driving innovation in the aging and brain health sector, supporting innovators through funding programs and commercialization guidance to enhance quality of life.
What's next for Mesosil?
With this major enterprise-level funding, Mesosil is poised to expand its operational footprint and deepen its research into clinical applications for implantable devices. The strategic roadmap focuses on scaling manufacturing partnerships and securing regulatory milestones necessary for broader market adoption. By leveraging the expertise of its diverse investor base, the company intends to solidify its position as a leader in the biomaterials sector, addressing the persistent challenge of infection prevention in clinical settings. Future growth will likely be driven by the commercialization of its dental product line and the successful validation of its technology in orthopedic applications, ensuring long-term value creation for stakeholders.
See full Mesosil company page
